Module

Interferon and Ribavirin: Mechanisms of Action, Resistance, and Why It Matters

Source: Hepatitis Annual Update 2006

Interferon and Ribavirin: Mechanisms of Action, Resistance, and Why It Matters

CME Program Director: Emmet B. Keeffe, MD, MACP

Faculty:

Raymond T. Chung, MD

CREDIT INFORMATION

Release Date: 08/03/06

Expiration Date: 08/02/07

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.6 Nursing contact hours

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the epidemiology, natural history, and life cycle of hepatitis C virus (HCV)
Review mechanisms of current approaches for the treatment of HCV
Recount the rationale and potential for novel agents in the treatment of HCV

Topics covered include:

Epidemiology and Natural History of Hepatitis C Virus (HCV)
Resistance to Interferon and Ribavirin
Viral Kinetics of HCV
Mechanisms of Action of Antiviral Agents: Interferon
Mechanisms of Action of Antiviral Agents: Ribavirin
Impact of Current Agents’ Characteristics on Selection of Future Antiviral Therapy
The Virus Fights Back: HCV Subversion of Antiviral Defenses
Therapeutic Strategies for Circumventing Viral Roadblocks: Innate Immunity
Future Contenders in Anti-HCV Therapy
Summary—Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.